Title : An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.

Pub. Date : 2015 Jul

PMID : 25964201






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Interestingly, cross-resistance to imatinib and enzastaurin (selective inhibitors of c-Kit and PKC-beta, respectively), was observed and the use of YK-4-279 with enzastaurin in vitro led to marked drug synergy, suggesting a potential role for combination therapies in the future. Imatinib Mesylate protein kinase C beta Homo sapiens